https://scholars.lib.ntu.edu.tw/handle/123456789/582056
標題: | Molecular epidemiology of hepatitis B virus | 作者: | JIA-HORNG KAO | 關鍵字: | Antiviral agents; Genotype; Hepatitis B virus; Hepatocellular carcinoma; Molecular epidemiology | 公開日期: | 2011 | 卷: | 26 | 期: | 3 | 起(迄)頁: | 255-261 | 來源出版物: | Korean Journal of Internal Medicine | 摘要: | Although safe and effective vaccines for hepatitis B virus (HBV) have been available for nearly three decades, this virus kills at least 600,000 people annually worldwide and remains the leading global cause of chronic hepatitis, cirrhosis, and hepatocellular carcinoma. Because the HBV reverse transcriptase lacks a proofreading function, many HBV genotypes, subgenotypes, mutants, and recombinants exist. At least 10 HBV genotypes (HBV-A through J) with distinct geographic distributions have been identified; by definition, their complete genomic sequences diverge by more than 8%. HBV genotype is increasingly becoming recognized as an important factor in the progression and clinical outcome of HBV- induced disease. Infections by HBV-C or -D are significantly more likely to lead to cirrhosis and hepatocellular carcinoma than are infections by HBV-A or -B. Additionally, the hepatitis B e antigen seroconversion response to standard or pegylated interferon is more favorable in patients with HBV-A or -B than in those with HBV-C or -D. However, therapeutic responses to nucleos(t)ide analogues are generally comparable among HBV genotypes. In conclusion, genotyping of HBV is useful in identifying chronic hepatitis B patients who are at increased risk of disease progression, thereby enabling physicians to optimize antiviral therapy for these patients. ? 2011 The Korean Association of Internal Medicine. |
URI: | https://www.scopus.com/inward/record.uri?eid=2-s2.0-80054855341&doi=10.3904%2fkjim.2011.26.3.255&partnerID=40&md5=684e612c8386ac543632e3d66c07652b https://scholars.lib.ntu.edu.tw/handle/123456789/582056 |
ISSN: | 1226-3303 | DOI: | 10.3904/kjim.2011.26.3.255 | SDG/關鍵字: | adefovir dipivoxil; alpha interferon; entecavir; hepatitis B surface antigen; hepatitis B(e) antigen; lamivudine; peginterferon alpha; RNA directed DNA polymerase; telbivudine; tenofovir disoproxil; article; cancer incidence; cancer risk; disease association; disease course; disease severity; drug efficacy; drug safety; gene sequence; genomics; genotype; geographic distribution; hepatitis B; Hepatitis B virus; high risk population; human; infection risk; liver cell carcinoma; liver cell damage; liver cirrhosis; molecular epidemiology; nonhuman; pathogenesis; prevalence; risk factor; seroconversion; treatment response; virus mutant; virus recombinant; virus resistance; virus strain; virus transmission; Antiviral Agents; Drug Resistance, Viral; Genotype; Hepatitis B; Hepatitis B virus; Humans; Molecular Epidemiology; Phenotype; Prognosis |
顯示於: | 臨床醫學研究所 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。